Bellicum Pharmaceuticals (NASDAQ:BLCM) Shares Cross Below 200-Day Moving Average of $0.40

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCMGet Free Report)’s share price crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $0.40 and traded as low as $0.16. Bellicum Pharmaceuticals shares last traded at $0.19, with a volume of 61,587 shares.

Analyst Upgrades and Downgrades

Separately, began coverage on Bellicum Pharmaceuticals in a research report on Thursday. They set a “sell” rating for the company.

Check Out Our Latest Research Report on Bellicum Pharmaceuticals

Bellicum Pharmaceuticals Stock Down 16.9 %

The stock’s 50 day simple moving average is $0.25 and its 200 day simple moving average is $0.40.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Bellicum Pharmaceuticals stock. Boxer Capital LLC acquired a new position in Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCMFree Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 450,000 shares of the biopharmaceutical company’s stock, valued at approximately $167,000. Boxer Capital LLC owned approximately 4.74% of Bellicum Pharmaceuticals at the end of the most recent quarter. Hedge funds and other institutional investors own 4.93% of the company’s stock.

About Bellicum Pharmaceuticals

(Get Free Report)

Bellicum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen.

See Also

Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with's FREE daily email newsletter.